MDMB-4en-PINACA: Complete Seizure, Fatal Toxicology, Withdrawal & Safety Monograph

MDMB-4en-PINACA: Complete Seizure, Fatal Toxicology, Withdrawal & Safety Monograph

Emergency warning: Seizure, collapse, severe loss of consciousness, abnormal breathing, dangerous agitation/confusion, chest pain, severe hypotension/weakness, or repeated vomiting after a synthetic cannabinoid or unknown “cannabis” product requires urgent medical care.

Quick answer

MDMB-4en-PINACA is a highly potent synthetic cannabinoid receptor agonist with a substantial and rapidly growing human toxicology record.

It is not “another form of THC.”

The strongest current evidence includes:

• 202 emergency presentations in a 2026 UK series;
• frequent loss of consciousness and seizures;
• direct deaths including cases where routine expanded toxicology initially failed to identify the drug;
• involuntary exposure through products believed to be ordinary low-THC cannabis;
• detection in adulterated retail tianeptine products;
• strong high-efficacy CB1 pharmacology.

Identity and history

MDMB-4en-PINACA is part of the “4en” SCRA generation, in which an unsaturated pentenyl side chain appears in compounds that emerged as the synthetic-cannabinoid market adapted to earlier controls.

Why this is not ordinary cannabis pharmacology

Natural cannabis intoxication is driven mainly by Δ9-THC, a partial CB1 agonist.

MDMB-4en-PINACA acts as a potent, high-efficacy/full agonist in multiple CB1 signaling assays.

Published in-vitro work found activity in the low-nanomolar range and efficacy that can exceed older reference SCRAs.

What those numbers mean—and do not mean

They support a high-hazard receptor mechanism.

They do not establish:

• a human “times stronger than THC” dose ratio;
• a safe consumer dose;
• a blood concentration that predicts seizure or death.

2026 emergency-department series: 202 presentations

A 2026 UK observational study analyzed 202 hospital presentations involving 163 patients with analytically confirmed MDMB-4en-PINACA exposure.

Common findings were:

• reduced level of consciousness: 81.2%;
• agitation: 49%;
• seizures: 30.2%;
• hypotension: 22.3%;
• elevated blood lactate: 47%;
• elevated creatine kinase: 38.1%.

There were four deaths.

The polysubstance caveat matters

In 178 of 202 presentations (88.1%), more than one recreational substance was detected.

Only 15 presentations had MDMB-4en-PINACA analytically confirmed as the only substance.

Therefore:

• the series strongly establishes clinical relevance;
• it does not give a clean single-drug probability for every symptom.

Seizures

Seizures are one of the clearest serious signals for MDMB-4en-PINACA.

They occurred in roughly three in ten presentations in the large UK series.

A seizure may also contribute to:

• lactic acidosis;
• rhabdomyolysis;
• aspiration;
• trauma;
• prolonged altered consciousness.

Recurrent or first-time seizure is an emergency.

Reduced consciousness and respiratory risk

Profound loss of consciousness was the most common feature in the 2026 series.

Severe CNS depression creates risks including:

• airway obstruction;
• aspiration;
• hypoxia;
• injury from collapse;
• respiratory compromise.

Synthetic cannabinoid intoxication should therefore not be dismissed as “just being too high.”

Agitation, paranoia and psychosis

SCRAs can produce apparently opposite CNS presentations:

• profound sedation in one patient;
• severe agitation/paranoia in another;
• alternating agitation and reduced consciousness.

Potential psychiatric effects include:

• panic;
• paranoia;
• hallucinations;
• psychosis;
• confusion;
• amnesia.

This variability is characteristic of an unpredictable high-efficacy receptor agonist plus variable product composition.

Hypotension, lactate and muscle injury

The UK series also documented:

• hypotension;
• elevated lactate;
• elevated creatine kinase.

These findings can reflect severe physiologic stress, seizures, prolonged agitation, immobility, hypoperfusion or combinations of factors.

Clinically significant CK elevation raises concern for rhabdomyolysis and kidney injury.

Fatality evidence: Cook County Jail

A 2025 case series described deaths in Cook County Jail after use of paper strips suspected of carrying synthetic cannabinoid.

A particularly important analytical finding was that expanded toxicology panels initially did not detect an illicit drug.

Additional targeted synthetic-cannabinoid testing identified MDMB-4en-PINACA.

The authors concluded that isolated use could potentially lead to death.

Why this matters

A negative broad toxicology panel is only as broad as its analyte library.

Novel SCRAs can sit outside a laboratory's routine scope.

Involuntary exposure through cannabis products

A European clinical/analytical series reported 13 patients who developed intoxication after consuming what they believed were low-THC cannabis products.

All cases had altered mental status.

Additional features included:

• seizures in five;
• paranoia in six;
• vomiting in six;
• hallucinations;
• amnesia.

MDMB-4en-PINACA was analytically identified in urine, blood and/or the implicated material.

This directly demonstrates that someone can be exposed to an SCRA without intending to use one.

Adulterated tianeptine products

A New Jersey poison-center investigation of a retail-product outbreak found highly variable contents in products marketed around tianeptine.

Product testing identified mixtures that could include:

• tianeptine;
• kava alkaloids;
• natural cannabinoids;
• MDMB-4en-PINACA;
• ADB-4en-PINACA.

Among acute toxicity calls in the outbreak, altered mental status, tachycardia, hypotension and seizures were common; many patients required ICU care or intubation.

Because product mixtures varied, those clinical outcomes cannot all be assigned specifically to MDMB-4en-PINACA.

The outbreak is nevertheless powerful evidence for retail-product identity uncertainty.

Product forms and high-concentration spots

SCRAs have appeared on:

• plant material;
• paper;
• e-liquids;
• powders;
• adulterated cannabis;
• other retail products.

Uneven distribution can create high-concentration spots within a product.

This site does not provide preparation or dilution instructions; the safety implication is that visual inspection cannot establish dose uniformity.

Metabolism

MDMB-4en-PINACA is extensively metabolized.

Human-hepatocyte/microsome and authentic-sample studies describe pathways such as:

• ester hydrolysis;
• hydroxylation;
• oxidation of the pentenyl side chain;
• additional oxidative transformations;
• glucuronidation/conjugation.

Specific metabolite patterns can help distinguish true exposure from structurally related SCRAs.

Testing and screening tactics

Routine THC testing

Standard cannabis immunoassays target THC metabolites.

They do not reliably detect MDMB-4en-PINACA.

Routine expanded toxicology

Even relatively broad panels can miss a newly emerging SCRA if it is not in the library, as illustrated by the jail fatalities.

Definitive methods

Testing may require:

• LC-MS/MS;
• LC-HRMS/QTOF;
• updated spectral libraries;
• parent drug + metabolite targets;
• authentic reference material.

Urine metabolite strategies can be particularly important because parent drug may be low or short-lived.

Human pharmacokinetics: still largely unknown

Despite the large clinical series, controlled human PK is not well established.

There is no validated population estimate for:

• bioavailability by route;
• time to peak;
• terminal half-life;
• accumulation;
• dose-concentration relationships;
• active-metabolite contribution.

Clinical observation duration is not a direct half-life measurement.

Interactions

Other SCRAs/cannabis

Can create additive or qualitatively different cannabinoid-receptor effects.

Benzodiazepines/alcohol/other sedatives

Can worsen altered consciousness, airway risk and accidents.

Stimulants

Can add cardiovascular and psychiatric stress.

Opioids

Mixed exposure can produce both cannabinoid toxicity and opioid respiratory depression.

If someone is unresponsive with slow/abnormal breathing after an unknown product, naloxone is appropriate when opioid exposure is possible. Naloxone does not reverse MDMB-4en-PINACA itself.

Tolerance and dependence

Frequent SCRA exposure can produce tolerance and physical dependence.

MDMB-4en-PINACA-specific dependence incidence has not been prospectively quantified.

The strongest conclusion is class-based:

high-efficacy CB1 agonists can produce a more severe dependence/withdrawal syndrome than natural cannabis in some frequent users.

Synthetic cannabinoid withdrawal

A 2025 systematic review of published withdrawal case reports identified symptoms including:

• psychosis;
• agitation/irritability;
• nausea/vomiting;
• seizures;
• tachycardia;
• insomnia;
• occasionally delirium, rhabdomyolysis and hallucinations.

Symptoms often began within 24–48 hours in the small case-report literature.

Do not convert that into an MDMB-4en-PINACA timeline

The review pooled different synthetic cannabinoids.

No prospective study establishes a compound-specific:

• withdrawal onset;
• peak;
• duration;
• seizure incidence;
• taper protocol.

Dependence vs use disorder

Physical dependence means withdrawal occurs when exposure stops.

A synthetic-cannabinoid use disorder also includes behavioral features such as:

• craving;
• inability to reduce use;
• escalating consumption;
• continuing despite seizures/hospitalization;
• hazardous use;
• interference with responsibilities.

They overlap but are not identical.

Treatment and support

No medication is approved specifically for MDMB-4en-PINACA withdrawal or synthetic-cannabinoid use disorder.

Management is driven by:

• acute complications;
• psychiatric symptoms;
• seizure risk;
• hydration/nutrition;
• co-occurring substance use.

Seizures, delirium, severe psychosis, persistent vomiting/dehydration, major cardiovascular instability or suicidality can require urgent/inpatient care.

U.S. support:

• FindTreatment.gov
• SAMHSA National Helpline: 1-800-662-HELP (4357)

Forensic interpretation

Detection vs causation

A postmortem positive establishes exposure.

Determining contribution or sole causation requires:

• co-drugs;
• autopsy findings;
• specimen type;
• scene evidence;
• analytical specificity;
• timing.

Routine-negative does not mean drug-free

The Cook County cases demonstrate this directly.

No universal lethal concentration

There is no validated MDMB-4en-PINACA blood threshold that predicts death for an individual.

High potency and low measured concentrations make analytical sensitivity essential.

Special populations

Controlled data are inadequate for:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• cardiovascular disease;
• seizure disorders;
• kidney/liver disease;
• serious psychiatric illness.

The large UK series included ages 14–78, showing that exposure is not restricted to a narrow young-adult population, but the study was not designed to estimate age-specific risk.

Legal and regulatory history

International

The UN Commission on Narcotic Drugs placed MDMB-4en-PINACA in Schedule II of the 1971 Convention on Psychotropic Substances in 2021.

United States

DEA temporarily placed MDMB-4en-PINACA in Schedule I on December 12, 2023.

Temporary control was extended during permanent scheduling proceedings.

DEA then permanently placed MDMB-4en-PINACA in Schedule I effective April 24, 2026, DEA code 7090.

Myths and misconceptions

“It is just synthetic cannabis.”
False as a safety comparison. It is a high-efficacy SCRA with seizures, loss of consciousness and deaths documented.

“If a cannabis product looks normal, it cannot contain an SCRA.”
False. Involuntary exposure through cannabis products is documented.

“Retail tianeptine labels tell you all active ingredients.”
False. An outbreak investigation found synthetic cannabinoids in some samples.

“A broad tox screen would definitely find it.”
False. Fatal cases initially tested negative until SCRA-specific analysis was performed.

“A low blood concentration means a mild exposure.”
Not necessarily. Potent SCRAs can be active at very low concentrations.

“Synthetic cannabinoid withdrawal is basically ordinary cannabis withdrawal.”
Potentially misleading. Published SCRA withdrawal cases include seizures, psychosis and delirium.

Evidence ledger

Related evidence

• 5F-ADB / 5F-MDMB-PINACA
• Synthetic cannabinoids guide
• ADB-4en-PINACA
• 4F-MDMB-BINACA
• Substance Use, Dependence & Harm Reduction hub

Bottom line

MDMB-4en-PINACA now has enough human evidence that calling it merely an “emerging research chemical” understates the case.

A 2026 clinical series documents hundreds of presentations with frequent loss of consciousness and seizures; fatal cases show how routine toxicology can miss it; and outbreak investigations prove people can encounter it in products sold as something else.

The high-value lesson is not a potency multiplier.

It is high-efficacy CB1 pharmacology + product-identity uncertainty + seizure/LOC risk + testing blind spots + real dependence/withdrawal potential.